BioMimetic (BMTI) Down as FDA Doesn't Approve Augment Bone Graft PMA in Current Form

BioMimetic Therapeutics, Inc. (Nasdaq: BMTI) shares are slumping in after-hours trading, following reports that the FDA would need more information needed for approval of its Pre-Market Approval (PMA) application for Augment Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures. Shares are down about 4 percent.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Hyperfine wins FDA clearance for updated portable MRI software
• AbbVie lung cancer drug data shows high response rates at WCLC 2026